Antiseizure drugs Flashcards
1
Q
Phenytoin, fosphenytoin
A
- Cyclic ureide
- MOA
- block high-frequency firing of neurons through action on VG Na+ channels
- decrease synaptic release of glutamate
- Kinetics
- zero-order
- highly bound to plasma proteins
- no active metabolites
- dose-dependent elimination, t1/2 12-36h
- fosphenytoin is for IV, IM routes
- Clinical
- generalized tonic-clonic seizures, partial seizures
- Tox, int.
- tox: diplopia, ataxia, gingival hyperplasia, hirsutism, neuropathy
- int: any drug that binds to plasma proteins
2
Q
Phenobarbital (cyclic ureide)
A
- MOA
- enhances phasic GABAA receptor responses, reduces excitatory synaptic responses
- Kinetics
- nearly complete absorption, not significantly bound to plasma proteins
- peak conc in 0.5-4h, no active metabolites, t1/2 varies from 75-125h
- Clinical
- generalized tonic-clonic seizures, partial seizures, myoclonic seizures, generalized seizures, neonatal seizures, status epilepticus
- Tox, int.
- tox: sedation, cognitive issues, ataxia, hyperactivity
- int: so many drugs
3
Q
Ethosuximide
A
- Cyclic ureide
- MOA
- reduces low-threshold Ca2+ currents (T-type)
- Kinetics
- well absorbed orally, peak levels in 3-7h, not protein-bound, completely metabolized to inactive compounds, t1/2 typically 40h
- Clinical
- absence seizures
- Tox, int.
- tox: nausea, headache, dizziness, lethargy
- int: valproate, phenobarbital, phenytoin, carbamazepine, rifampacin
4
Q
Carbamazepine
A
- Tricyclic
- MOA
- blocks high-frequency firing of neurons through action on VG Na+ channels
- decreases synaptic release of glutamate
- Kinetics
- well absorbed orally, peak levels in 6-8h, no significant protein binding, metabolized in part to active 10-11-epoxide
- t1/2 8-36h
- Clinical
- generalized tonic-clonic seizures, partial seizures
- Tox, int.
- tox: nausea, diplopia, atazia, hyponatremia, headache
- int: many
5
Q
Diazepam
A
- MOA
- potentiates GABAA responses
- Kinetics
- well absorbed orally, rectal administration gives peak conc in approx 1h with 90% bioavailability
- IV for status epilepticus
- highly protein bound, extensively metabolized to several active metabolites, t1/2 2d
- Clinical
- status epilepticus, seizure clusters
- Tox, int.
- tox: sedation
- int: additive with sedative-hypnotics
6
Q
Clonazepam
A
- MOA
- potentiates GABAA responses
- Kinetics
- >80% bioavailability, extensively metabolized but no active metabolites, t1/2 20-50h
- Clinical
- absence seizures, myoclonic seizures, infantile spasms
- Tox, int.
- tox: sedation
- int: additive with sedative-hypnotics
7
Q
Vigabatrin
A
- GABA derivate
- MOA
- irreversibly inhibits GABA-transaminase
- Kinetics
- 70% bioavailable, not bound to plasma proteins, not metabolized
- Clinical
- partial seizures, infantile spasms
- Tox, int.
- tox: drowsiness, dizziness, psychosis, visual field loss
- int: minimal
8
Q
Valproate
A
- MOA
- blocks high-frequency firing of neurons, modifies amino acid metabolism
- Kinetics
- well absorbed from several formulations, highly bound to plasma proteins, extensively metabolized, t1/2 9-16h
- Clinical
- generalized tonic-clonic seizures, partial seizures, generalized seizures, absence seizures, myoclonic seizures
- Tox, int.
- tox: nausea tremor, weight gain, hair loss, teratogenic, hepatotoxic
- int: many
9
Q
Lamotrigine
A
- MOA
- prolongs inactivation of VG Na+ channels
- acts presynaptically on VG Ca2+ channels, decreasing glutamate release
- Kinetics
- well absorbed orally, no significant protein binding, extensively metabolized but no active metabolites, t1/2 25-35h
- Clinical
- generalized tonic-clonic seizures, generalized seizures, partial seizures, absence seizures
- Tox, int.
- tox: dizziness, headache, diplopia, rash
- int: many
10
Q
Levetiracetam
A
- MOA
- action on synaptic protein SV2A
- Kinetics
- well absorbed orally, not bound to plasma proteins, metabolized to 3 inactive metabolites, t1/2 6-11h
- Clinical
- generalized tonic-clonic seizures, partial seizures, generalized seizures
- Tox, int.
- tox: nervousness, dizziness, depression, seizures
- int: rare